Cat allergy immunotherapy(Circassia Group Plc)(Cat allergy immunotherapy(Circassia Group Plc))

概要

基本信息

药物类型

治疗性疫苗

别名

Cat allergen vaccine、Cat allergy immunotherapy、Cat-PAD

+ [3]

靶点-

作用方式

调节剂

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症-

非在研适应症

哮喘猫过敏（疾病）结膜炎+ [3]

原研机构

Niox Group Plc

在研机构-

非在研机构

Circassia Ltd.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

22

项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的临床试验

ISRCTN17973296

/ Completed早期临床1期

An open label, safety and allergenicity Phase 0 study of a new hypoallergenic plant-derived cat dander vaccine in adult cat allergic subjects

开始日期2023-09-14

申办/合作机构-

NCT02795273

/ Withdrawn临床2/3期

A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis

The purpose of this study is to evaluate the safety of Grass-SPIRE compared with placebo and to evaluate the treatment effect of Grass-SPIRE on symptoms and use of rescue medication during the grass pollen season

开始日期2016-05-01

申办/合作机构

Circassia Ltd.

NCT02478060

/ Completed临床2期

A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE

The purpose of this study is to evaluate the safety and tolerability of multiple administrations of Birch-SPIRE. To make a preliminary assessment on pharmacodynamic parameters and clinical outcomes.

开始日期2015-07-01

申办/合作机构

Circassia Ltd.

[+2]

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的临床结果

登录后查看更多信息

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的转化医学

登录后查看更多信息

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的专利（医药）

登录后查看更多信息

4

项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的文献（医药）

2021-06-01·Allergy

Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre‐ and post‐peptide immunotherapy: An open‐label clinical study

Letter

作者: Ellis, Anne K. ; Tebbutt, Scott J. ; Tonti, Elena ; Hickey, Pascal ; Neighbour, Helen ; Kim, Young Woong ; Larché, Mark

This article immunol. changes in peripheral blood samples obtained from individuals with allergic rhinitis (AR), triggered by exposure to cat allergen, who were receiving peptide immunotherapy.Ten cat-sensitized AR individuals received cat-peptide antigen desensitization peptide immunotherapy for AR; participants were treated with four intradermal injections (at 4-wk intervals) of 6 nmol Cat-PAD.In analyses of complete blood count (CBC) data, frequencies of immune cells neutrophils, lymphocytes, and monocytes at V3 were significantly different from at V1A.Lower expression of immune genes at V3 was associated with IL-2-, IL-4-, IL-6-, granulocyte-macrophage colony-stimulating factor and B-cell receptor signaling pathway-mediated signaling events; conversely, higher expression of immune genes at V3 was associated with T-cell receptor signaling in CD4+ and CD8+ T cells and IL-12-mediated signaling events.Five immune genes with significant gene expression patterns were identified: integrin subunit alpha E (ITGAE, CD103), CD180 (LY64), (NCAM1, CD56), C-C motif chemokine receptor 7 (CCR7, CD197), And leucine-rich repeat neuronal 3 (LRRN3).Cellular and genetic approaches in peripheral blood with NAC may identify predictors of treatment efficacy and better pheno- or endo-typing for precision medicine.

2013-10-01·Expert Opinion on Investigational Drugs2区 · 医学

Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis

2区 · 医学

Review

作者: Margitta Worm ; Deepan Patel ; Peter Socrates Creticos

INTRODUCTIONAllergic rhinoconjunctivitis is an increasingly common source of morbidity with sensitivity to cats accounting for 10-15% of the disease burden. Allergy to cats is a major risk factor for the development of asthma.AREAS COVEREDWithin the present manuscript, the current data on a novel therapeutic approach to treat cat allergy is reviewed. Cat Peptide Antigen Desensitisation (Cat-PAD) is a mixture of seven small peptides developed for the treatment of cat allergy. It is designed to induce immunological tolerance via binding to MHC class II on antigen presenting cells and interacting with regulatory T cells without triggering the cross-linking of IgE on mast cells and basophils. The peptide sequences are derived from the major cat allergen Fel d 1. The peptides have been selected to ensure a similar T cell response to that generated to whole cat dander in ex-vivo PBMC derived from cat allergic individuals. The size of the peptides is insufficient to induce cross-linking of IgE. Clinical data from a series of studies shows that Cat-PAD is able to significantly reduce allergic rhinoconjunctivitis symptoms after a short course of four injections over 12 weeks, and that the treatment effect is persistent lasting 2 years after the start of treatment.EXPERT OPINIONTaken together Cat-PAD is a novel, well tolerated and promising therapeutic approach to treat cat allergic patients. Data from the current international Phase III study will unravel whether the concept is also efficient and tolerable under daily life circumstances.

2013-01-01·Journal of Allergy and Clinical Immunology1区 · 医学

Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study

1区 · 医学

Article

作者: Pascal Hickey ; Peter Couroux ; Paul Laidler ; Roderick P. Hafner ; Deepen Patel ; Anne Marie Salapatek ; Mark Larché

BACKGROUNDAllergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma.OBJECTIVESWe sought to probe the persistence of the treatment effect of a novel F el d 1-derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy-induced rhinoconjunctivitis after standardized allergen challenge.METHODSIn a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment.RESULTSTreatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = .0342) and placebo (P = .0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year.CONCLUSIONSA short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment.

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
猫过敏（疾病）	临床3期	-	Circassia Ltd.	2014-02-01
鼻结膜炎	临床3期	比利时	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	俄罗斯	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	美国	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	斯洛伐克	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	匈牙利	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	德国	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	捷克	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	加拿大	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	波兰	Circassia Ltd.	2012-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01620762 (CTgov)	临床3期	鼻结膜炎	1,408	Placebo	艱窪淵簾蓋獵鏇製鹽築(鏇製憲顧獵獵鑰鹹觸憲) = 襯衊鹽窪鑰糧構獵艱鑰壓築蓋夢鑰網鏇襯壓鹹 (願齋選鹹餘鏇積選鏇廠, 醖襯壓夢構鹹積蓋築糧 ~ 簾鹽窪鏇簾餘壓壓鬱膚) 更多	-	2018-05-14
NCT02040844 (CTgov)	临床3期	猫过敏（疾病）	430	placebo (Cat-PAD Treatment 1 (1 Course))	鬱窪積窪築膚積願襯糧(醖遞築憲壓鬱鏇艱鏇鏇) = 選窪壓襯鏇觸選鹽壓顧顧廠簾憲襯觸選構構醖 (獵選糧夢餘鹹夢選獵鏇, 餘鏇遞繭蓋憲積繭糧窪 ~ 顧製艱憲觸壓鹹窪鬱齋) 更多	-	2018-05-14
NCT02040844 (CTgov)	临床3期	猫过敏（疾病）	430	Cat-PAD (Cat-PAD Treatment (2 Courses))	鬱窪積窪築膚積願襯糧(醖遞築憲壓鬱鏇艱鏇鏇) = 艱艱遞製觸蓋憲鑰積廠顧廠簾憲襯觸選構構醖 (獵選糧夢餘鹹夢選獵鏇, 糧窪窪鹹衊餘壓膚窪鬱 ~ 鏇觸膚構鏇蓋窪鑰積蓋) 更多	-	2018-05-14
ASCO2004	临床1/2期	多发性骨髓瘤	15	PAD combination	鬱膚範壓獵衊鬱襯簾築(顧糧襯齋淵壓憲鏇範夢) = 遞憲簾夢衊衊夢觸鹽顧築選鹽願衊憲選範衊鏇 (製繭糧淵鹽製顧襯餘餘 ) 更多	-	2004-07-15